Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. - Wikidata - wikimedia - TriplyDB

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

http://www.wikidata.org/entity/Q27851680

about

Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy Epigenetic regulators and their impact on therapy in acute myeloid leukemia Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia CIViC database IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Myelodysplastic syndromes: Contemporary review and how we treat.Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.Molecular pathophysiology of myelodysplastic syndromes.IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression Digging deep into "dirty" drugs - modulation of the methylation machinery.TET family proteins: oxidation activity, interacting molecules, and functions in diseases.What do we know about IDH1/2 mutations so far, and how do we use it?What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.The genetic basis of myelodysplasia and its clinical relevance Isocitrate dehydrogenase mutations in myeloid malignancies.IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.Isocitrate dehydrogenase mutations in leukemia.Stem cell origin of myelodysplastic syndromes.Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.I walk the line: how to tell MDS from other bone marrow failure conditions.5-hydroxymethylcytosine: a potential therapeutic target in cancer.Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?Roles of IDH1/2 and TET2 mutations in myeloid disorders.IDH mutations in cancer and progress toward development of targeted therapeutics.Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.Beyond the Oncogene Revolution: Four New Ways to Combat Cancer.Genetic stratification in myeloid diseases: from risk assessment to clinical decision support tool.Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight.TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

P2860

Q26749870-FED93C63-4596-42EF-86D2-94F8A2C46E4E Q26765402-F30A7912-BB62-4774-90FA-A5B6426F2A1D Q26768600-D5EC6A17-B799-4EB3-AC20-39DA653B0317 Q27612411-85887A94-87AC-4555-A5B8-7F8D2D1F6C86 Q28066926-814BBD23-EC11-41A8-8DBB-6F094C877C77 Q30235355-DA10FDDA-AD2B-42E8-8149-85E27CFBBAAA Q33429195-AD0936C0-9EE5-4CC8-A97F-E405473068C0 Q33558105-BFE73D23-9A4A-4755-80B4-DCE24B2E44C0 Q33769072-400C7072-D134-49C7-9DB9-A0B95A54D1E9 Q33945004-EF969EF7-2026-45A2-9409-FB28BD32735F Q34661033-85C23467-8588-4938-9161-B5A6832E90D5 Q34667249-58BD8BD6-77D0-4CB1-8CFF-F579EF9E32B1 Q36445968-D8FE0C7B-C87E-4C6D-81A7-E9DE9739FDE5 Q36522731-ABA139B8-38AE-4A88-88C7-B4F32703D610 Q36523796-245C075E-98A8-4E02-832E-809DAF641455 Q36668364-77C99A23-7316-4B81-BCBD-C2D62E7CBEE2 Q36788229-E016D520-5149-40A0-AC72-A4B276093B57 Q36832167-F97C95F7-354C-4A9E-B29E-BE219B99CA3F Q36928342-18024239-C3CA-43A3-900C-4A58E39128A8 Q37220129-E5F17808-0F6C-4011-8E78-1B3F1DB8ACE3 Q37390236-24C9418D-4E04-4011-B19A-B89FEE4A4FCE Q37625630-E4F7A057-8025-4745-9378-E66719C799DB Q37734751-5778B471-5194-4119-8B36-BEAD45D8027A Q38078427-CF21FEC8-9073-4B0F-98D6-B6D0AC88D578 Q38113961-3DE89773-5C4B-4483-BCED-511377852599 Q38122703-2C013DF9-2F40-403E-B538-BC36BC3FBBDA Q38129336-02F04C79-FC9E-4ED9-A8D0-6EDD895CFEAF Q38133721-B7C7B9FD-DE08-43FC-A775-218A3B2B436E Q38171230-230DFB1A-E021-4429-A4CE-C1631F751639 Q38218055-ECB47AA4-B419-4295-91E7-C81983B51A0C Q38235622-AE265C6A-AFFC-421B-AF2A-877CE0600833 Q38272312-EE63ADF4-AC04-461B-BEF0-38877053CDE6 Q38716306-9168B08B-7A09-42C4-ADBA-F0D7C9697D97 Q38775985-523633E4-2BFC-432C-9AD2-0B5D3376AC1D Q38785528-8C80C04A-18B1-4C3C-B09F-A947FFD39853 Q38953709-BE362705-D6AD-41E2-B245-9B16FDD7D15F Q39069239-8CD3907D-3F86-4F1F-B5C8-025CA8274196 Q39100115-A0960C71-8FC4-415D-8942-06175D48BD4A Q41247181-11F752E1-E5A3-4B3D-B8D8-978CD7A98E71 Q43711843-3820237F-AAE2-4B54-80B7-32D42AFD55B7

P2860

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

http://www.wikidata.org/entity/Q27851680

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Differential prognostic effect ...... Clinic study of 277 patients.

@ast

Differential prognostic effect ...... Clinic study of 277 patients.

@en

Differential prognostic effect ...... Clinic study of 277 patients.

@nl

type

label

Differential prognostic effect ...... Clinic study of 277 patients.

@ast

Differential prognostic effect ...... Clinic study of 277 patients.

@en

Differential prognostic effect ...... Clinic study of 277 patients.

@nl

prefLabel

Differential prognostic effect ...... Clinic study of 277 patients.

@ast

Differential prognostic effect ...... Clinic study of 277 patients.

@en

Differential prognostic effect ...... Clinic study of 277 patients.

@nl

P1433

Q27851680-AD126243-0FE2-472E-BB05-9952A3E22F0C

P1476

Q27851680-6DDDE7AC-7AC1-49A4-A5A2-80B2F52A9E31

P2093

Q27851680-1D6B7F63-0F8E-4037-8E0F-9A4754BE0BBB

Q27851680-330A0E5B-9BBA-4A00-807F-3171233A35F4

Q27851680-96037CF6-099E-4999-8FF5-F348DDF9A395

Q27851680-9C0B0F59-0775-4D63-B530-0659B157C245

Q27851680-A2E09029-8B78-4D50-A8C0-B81D23F66683

Q27851680-A75149F3-7D5F-487D-B3C9-039D98A2054D

Q27851680-EA78D2A0-CB11-48AA-80D5-4D0CDD79645C

Q27851680-F00BF59C-AF69-429E-91AB-11C3F55987B7

P2860

Q27851680-05D7CEF2-9DEA-4FDD-B496-64492792A7BB

Q27851680-107B0ABE-E97A-48CA-9429-E6F0BADB6B0D

Q27851680-28067845-0FD9-4773-AE0C-8BD7FF263523

Q27851680-30D4BF66-8E65-4A78-9761-6D088F3283F6

Q27851680-3316E5D9-E23E-49A7-B25D-F252BD06ADE0

Q27851680-3FB6F971-2CA2-4446-AF82-48BBE13F5D89

Q27851680-654AB33A-99B8-47FC-8570-71DB388E7EF7

Q27851680-682AF52D-9F96-4801-84BE-574AF691C86B

Q27851680-69B326B4-724E-4705-9599-F7377665E289

Q27851680-6D842018-7228-4E4C-BA11-38A3F8774876

P2888

Q27851680-1EC8BC8B-1A9B-453C-A45C-2464AE0714F3

P304

Q27851680-FD078D69-DDFC-43A4-A8AC-AF21662F3E91

P31

Q27851680-009F74BE-1B69-4FAF-B5AA-E96020C2D53E

P3181

Q27851680-40B2ACA5-8C84-4F5D-9DC0-89F22DD113DA

P356

Q27851680-4F9D705B-B8E5-40D7-BE78-3C6CC41F6E8F

P433

Q27851680-5ED94036-D6DB-4557-A3D7-D74A89091B81

P478

Q27851680-332D2A73-43D8-42C4-93E4-BC77444B9784

P50

Q27851680-AEC351C1-D82E-4C5E-9363-849373E13F4B

P577

Q27851680-6BF5038C-0C50-4386-9E4C-8C74636C579F

P5875

Q27851680-A327B5DD-00AE-46B2-8432-CD4601065E61

P6179

Q27851680-ECBB380C-7266-4C34-9119-F9C57FD57276

P698

Q27851680-9C3A45BF-A373-49E2-AC0B-D37F0BFE2508

P3181

P356

P1433

P1476

Differential prognostic effect ...... Clinic study of 277 patients.

@en

P2093

A Pardanani

http://www.w3.org/2001/XMLSchema#string

C A Hanson

http://www.w3.org/2001/XMLSchema#string

C M Finke

http://www.w3.org/2001/XMLSchema#string

J M Hodnefield

http://www.w3.org/2001/XMLSchema#string

M M Patnaik

http://www.w3.org/2001/XMLSchema#string

R A Knudson

http://www.w3.org/2001/XMLSchema#string

R P Ketterling

http://www.w3.org/2001/XMLSchema#string

T L Lasho

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Recurring mutations found by sequencing an acute myeloid leukemia genome

An integrated genomic analysis of human glioblastoma multiforme

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

P2888

P304

101-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3690021

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/LEU.2011.298

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51751182

http://www.w3.org/2001/XMLSchema#string

P6179

1002085731

http://www.w3.org/2001/XMLSchema#string

P698

22033490

http://www.w3.org/2001/XMLSchema#string